热门资讯> 正文
Elanco看到合同制造商面临破产影响EBITDA
2024-09-13 21:50
- Elanco Animal Health(ELAN) 0
- iShares LifePath Target Date 2025 ETF USD(ITDA) 0
- Informatica Inc.(NYSE) 0
- Elanco Animal Health (NYSE:ELAN) on Friday disclosed an approximately $5M-$10M impact on its adjusted EBITDA for 2024 after its contract manufacturing supplier TriRx Speke entered administration, a formal insolvency process in the U.K.
- The U.S.-owned TriRx has appointed administrators from FTI Consulting to oversee the process, designed to help financially challenged companies achieve stability.
- The U.S. veterinary products maker Elanco (ELAN) has a long-term supply pact with the Liverpool pharmaceutical plant to manufacture certain farm animal products.
- “Elanco is working constructively with the Administrators to support business continuity in the interim and explore possible options in the best interest of all stakeholders,” the company said, adding that it expects minimal supply disruption as a result.
- However, Elanco (ELAN) continues to expect its 2024 adjusted EBITDA will reach $900M-$940M.
More on Elanco
- Elanco Animal Health: Positioned For Success
- Elanco Animal Health (ELAN) Q2 2024 Earnings Call Transcript
- Elanco: Expect Solid Growth From 6 Blockbusters Despite Execution Uncertainty
- Elanco spikes as CEO buys over $1M stock
- Elanco Non-GAAP EPS of $0.30 beats by $0.06, revenue of $1.18B beats by $30M
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
